Sep 25, 2013 by Dave WilliamsonDon't Write Off This Lung Cancer Vaccine Just YetOncothyreon's lung cancer vaccine Stimuvax is gearing up for another phase 3 trial.
Sep 25, 2013 by Dave Williamson and Max Macaluso1 Hot Biotech No One Wants to BuyClovis Oncology can't find a buyer.
Sep 25, 2013 by Dave Williamson and Max MacalusoWill This Orphan Drugmaker Get a Parent Company?After rumors swirl around Alexion, it appears Roche may be looking to acquire BioMarin.
Sep 24, 2013 by Dave Williamson and Max MacalusoThe Dangerous Impact of Defunding ObamacareWhy defunding Obamacare will lead to problems for insurers like WellPoint and Aetna along with hospital stocks like Tenet.
Sep 22, 2013 by Dave Williamson and Max MacalusoInvesting Chicken: When to Sell Gilead SciencesWhat would it take for Gilead to become a bad investment
Sep 21, 2013 by Dave Williamson and Max Macaluso1 Great Dividend Stock for Growth InvestorsWhy Amgen's small but increasing dividend shouldn't be overlooked.
Sep 21, 2013 by Dave Williamson and Max MacalusoBig Pharma's Big Plans for New Fish Oil DrugThe FDA accepts AstraZeneca's new drug application for Epanova.
Sep 20, 2013 by Dave Williamson and Max MacalusoIs this Cancer-Fighting Biotech for Sale?Clovis Oncology is rumored to be the next biotech acquisition.
Sep 20, 2013 by Dave WilliamsonAsk a Fool: How Will ObamaCare Affect the Insurance Industry?Will ObamaCare fundamentally change how managed-care companies like UnitedHealth, Cigna, Aetna, and WellPoint operate?
Sep 19, 2013 by Dave Williamson and Max MacalusoDid the FDA Just Threaten Glaxo's Future?The FDA lowers the barrier to entry for Advair generics.
Sep 19, 2013 by Dave Williamson and Max MacalusoThis Diabetes Drug Never Had a ChanceSanofi surprisingly pulls its GLP-1 drug from Food and Drug Administration review.
Sep 18, 2013 by Dave Williamson and Max MacalusoWorld's Biggest Biotech Takes on CancerGilead files an NDA for Non-Hodgkin’s Lymphoma drug idelalisib.
Sep 16, 2013 by Dave WilliamsonAsk a Fool: What Does the New Health Care Reform Act Mean for the Vertical Health Care Industries?Here's why managed-care stocks are going to feel Obamacare the hardest.
Sep 14, 2013 by Dave WilliamsonIs This Diabetes Drug Stock in Jeopardy?And the larger implications of the Express Scripts decision.
Sep 14, 2013 by Dave WilliamsonFallout From This Heart-Drug FailureWhen a trial failure isn't all that bad.
Sep 14, 2013 by Dave Williamson and Max MacalusoGilead Investors' Nightmare ScenarioA what-if scenario featuring a potential blockbuster going bad.
Sep 14, 2013 by Dave WilliamsonIs Vivus a Rudderless Ship?A surprise resignation calls into question the company's direction.
Sep 11, 2013 by Dave Williamson and Max MacalusoGilead's Lurking Megablockbuster DrugSofosbuvir and the biotech's hepatitis-c pipeline have investors excited.
Sep 9, 2013 by Dave Williamson and Max Macaluso1 Biotech Pipeline Packed with PotentialWhy investors should be excited about Gilead's pipeline diversification.
Sep 8, 2013 by Dave Williamson3 Ways Obamacare Is Ending Business as UsualFrom employee spouses getting dumped from insurance, to expanded pharmacy care, and medical-device takeovers.
